Objective： To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer （SCLC）. Methods： Eligible patients with SCLC who had progressed or relapsed af...Objective： To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer （SCLC）. Methods： Eligible patients with SCLC who had progressed or relapsed after therapy were treated with cisplatin and irinotecan. The regimen consisted of irinotecan 60 mg/m^2 on days 1, 8, 15 and cisplatin 60 mg/m^2 on day 1; the plan was given every 28 days. Results： In 23 evaluable patients, responses included 5 complete remissions and 7 partial remissions （overall response rate, 43.4%）, 6 patients had stable disease and 7 had progressive disease. Median time to progression and median survival were 4.6 and 8.3 months. The main toxicities were the hematologic toxicity, nausea and vomiting. Grade Ⅲ, IV leukopenia were seen in 15 patients （65.2%）, thrombocytopenia was seen in 8 patients （34.8%）; Nausea and vomiting were seen in 19 patients （82.6%）; Grade Ⅲ, IV nausea and vomiting were seen in 4 patients （65.2%） and diarrhea was seen in 20 patients （87.0%）. There were no treatment-related deaths. Conclusion： The combination of irinotecan and cisplatin is highly active and tolerable in patients with relapsed SCLC when it is administered as second-line treatment.展开更多
文摘Objective： To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer （SCLC）. Methods： Eligible patients with SCLC who had progressed or relapsed after therapy were treated with cisplatin and irinotecan. The regimen consisted of irinotecan 60 mg/m^2 on days 1, 8, 15 and cisplatin 60 mg/m^2 on day 1; the plan was given every 28 days. Results： In 23 evaluable patients, responses included 5 complete remissions and 7 partial remissions （overall response rate, 43.4%）, 6 patients had stable disease and 7 had progressive disease. Median time to progression and median survival were 4.6 and 8.3 months. The main toxicities were the hematologic toxicity, nausea and vomiting. Grade Ⅲ, IV leukopenia were seen in 15 patients （65.2%）, thrombocytopenia was seen in 8 patients （34.8%）; Nausea and vomiting were seen in 19 patients （82.6%）; Grade Ⅲ, IV nausea and vomiting were seen in 4 patients （65.2%） and diarrhea was seen in 20 patients （87.0%）. There were no treatment-related deaths. Conclusion： The combination of irinotecan and cisplatin is highly active and tolerable in patients with relapsed SCLC when it is administered as second-line treatment.
